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BRIEF COMMUNICATION
Syndrome of Reversible Cardiogenic 
Shock and Left Ventricular Ballooning in 
Obstructive Hypertrophic Cardiomyopathy
Mark V. Sherrid , MD; Daniel G. Swistel, MD; Iacopo Olivotto , MD; Maurizio Pieroni , MD;    
Omar Wever- Pinzon , MD; Katherine Riedy, MD; Richard G. Bach, MD; Mustafa Husaini , MD;   
Sharon Cresci , MD; Alex Reyentovich, MD; Daniele Massera , MD; Martin S. Maron, MD;   
Barry J. Maron, MD; Bette Kim, MD
BACKGROUND: Cardiogenic shock from most causes has unfavorable prognosis. Hypertrophic cardiomyopathy (HCM) can 
uncommonly present with apical ballooning and shock in association with sudden development of severe and unrelenting left 
ventricular (LV) outflow obstruction. Typical HCM phenotypic features of mild septal thickening, outflow gradients, and distinc-
tive mitral abnormalities differentiate these patients from others with Takotsubo syndrome, who have normal mitral valves and 
no outflow obstruction.
METHODS AND RESULTS: We analyzed 8 patients from our 4 HCM centers with obstructive HCM and abrupt presentation of cardio-
genic shock with LV ballooning, and 6 cases reported in literature. Of 14 patients, 10 (71%) were women, aged 66±9 years, present-
ing with acute symptoms: LV ballooning; depressed ejection fraction (25±5%); refractory systemic hypotension; marked LV outflow 
tract obstruction (peak gradient, 94±28 mm Hg); and elevated troponin, but absence of atherosclerotic coronary disease. Shock 
was managed with intravenous administration of phenylephrine (n=6), norepinephrine (n=6), β- blocker (n=7), and vasopressin (n=1). 
Mechanical circulatory support was required in 8, including intra- aortic balloon pump (n=4), venoarterial extracorporeal membrane 
oxygenation (n=3), and Impella and Tandem Heart in 1 each. In refractory shock, urgent relief of obstruction by myectomy was 
performed in 5, and alcohol ablation in 1. All patients survived their critical illness, with full recovery of systolic function.
CONCLUSIONS: When cardiogenic shock and LV ballooning occur in obstructive HCM, they are marked by distinctive anatomic 
and physiologic features. Relief of obstruction with targeted pharmacotherapy, mechanical circulatory support, and myec-
tomy, when necessary for refractory shock, may lead to survival and normalization of systolic function.
Key Words: cardiogenic shock ■ hypertrophic cardiomyopathy ■ hypertrophic obstructive cardiomyopathy ■ left ventricular ballooning 
■ left ventricular outflow tract obstruction ■ supply- demand ischemia ■ Takotsubo syndrome
The course of obstructive hypertrophic cardiomy-opathy (HCM) can uncommonly but dramatically be punctuated by an acute syndrome with fea-
tures resembling an acute coronary syndrome, with 
left ventricular (LV) apical ballooning, that may occur 
in association with LV outflow gradients that become 
severe and unrelenting.1- 3 Indeed, 30% of an unse-
lected cohort of admitted patients with Takotsubo syn-
drome have typical phenotypic features of obstructive 
HCM, including mild septal thickening, high outflow 
gradients, elongated mitral leaflets, anterior position 
of the valve, and anomalous anterior papillary mus-
cles/shortened chordae.1 In these patients however, 
obstructive HCM may be overlooked because of the 
dramatic presentation, because the septal thickening 
is mild (average, 15 mm),1,2 and because obstruction 
may be latent. In this study, we report 14 patients with 
HCM who developed cardiogenic shock because of 
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this syndrome, whose treatment importantly differed 
from other causes of shock. Diagnosis is key, as the 
extent of permanent myocardial damage is diminutive 
despite the extensive short- term decrease in ejection 
fraction, and permits rapid return of normal LV systolic 




To appreciate this unique syndrome, we compiled in-
formation from our previously published reports in the 
literature of 7 patients who presented to our 4 HCM 
centers. One recent case that we cared for is described 
herein for the first time without personal health infor-
mation. We also summarized 6 relevant single case 
reports from other authors reported in the literature.4- 9 
Because in the present article we review the previously 
published data in 13 patients and there is no identify-
ing patient information, our institutional review board 
determined that this work did not meet the definition of 
human subject research and therefore, approval was 
not required. The materials used for this report will be 
shared with researchers on request. Summary statis-
tics are presented as mean±SD.
RESULTS
Fourteen patients, aged 65.6±9 years, with 10 women 
(71%), had hypotension at admission (systolic blood 
pressure [BP], 74±9  mm  Hg) and evidence of shock 
and greatly reduced LV ejection fraction (25±5%). 
Echocardiographic LV outflow peak gradient at rest 
was 94±28 mm Hg. Septal thickness was 16±3 mm 
(range, 12– 20 mm). At angiography, no patient had sig-
nificant coronary atherosclerotic stenosis (Tables  S1 
and S2).
All patients showed LV ballooning with akinesia or 
dyskinesia of the apical- mid segments with preser-
vation of basal contraction. During the LV ballooning 
event, there was marked mitral valve systolic anterior 
motion (SAM) with mitral- septal contact. Severe mi-
tral regurgitation attributable to SAM was present in 
5 patients, whereas the other patients showed milder 
degrees (Table  S2). Figures  1 and 2 show multimo-
dality imaging of a recent representative patient. ECG 
abnormalities were as follows: ST- segment elevation 
(n=7), ST depression or diffuse T- wave inversion (n=4), 
or left bundle- branch block (n=2). Low- grade cardiac 
biomarker elevations were noted in all.
One patient had survived a prior episode of api-
cal ballooning. Inciting events to acute deterioration 
included 7 patients with new- onset medical illness 
(including 4 with new onset of atrial fibrillation as 
a contributing factor), 4 with emotional triggers, 1 
after severe physical exertion, and 2 with no evident 
trigger.
Details of treatment administered are shown in 
the Table. Copious intravenous fluids were adminis-
tered in 4 patients. There was no improvement from 
conventional inotropic therapy with dopamine and 
dobutamine. These agents were terminated in favor 
of phenylephrine, norepinephrine, or vasopressin. 
Intravenous β- blockade was administered to 7 patients 
despite the low BP and low cardiac output state; in 6 
patients, β- blockers were administered concomitantly 
with phenylephrine to support BP. Pharmacotherapy 
stabilized 6 (43%) patients, allowing weaning from va-
soactive medications, with return of baseline systolic 
LV function.
However, 8 patients required mechanical inter-
ventions, sometimes multiple: intra- aortic balloon 
counterpulsation (n=4), venoarterial extracorpo-
real membrane oxygenation (VA- ECMO) (n=3), and 
Impella and Tandem Heart in 1 each. Failing these 
measures, 5 patients had urgent surgical myectomy, 
2 with concomitant mitral valve replacement because 
maximal septal thickness was only 16 and 17 mm, re-
spectively. One patient with multisystem failure, too ill 
for myectomy, underwent alcohol septal ablation. All 
patients survived their acute shock events; LV sys-
tolic function normalized hours to weeks after relief of 
outflow obstruction. In 2 patients, there was marked 
improvement in systolic function within 2  hours of 
their operation. One additional patient with HCM 
required myectomy for limiting symptoms 4 months 
after his LV ballooning event.
DISCUSSION
The 14 patients with HCM analyzed herein devel-
oped cardiogenic shock attributable to high LV out-
flow peak gradients (average, 94 mm Hg) associated 
with LV ballooning with apical and mid- LV wall motion 
abnormality. These patients present with features re-
sembling an acute coronary syndrome, but are found 
to have normal coronary angiograms; as such, their 
presentation mimics Takotsubo syndrome. However, 
such patients with HCM have distinctive anatomic and 
physiologic characteristics that set them apart from 
the larger group of patients with Takotsubo syndrome 
who have no outflow obstruction, normal mitral valves, 
and normal septal thickness.1,2 Such distinction is im-
portant in both the short- term clinical phase because 
of requirement for HCM- specific treatment options 
that differ from Takotsubo syndrome management and 
long- term.
LV systolic dysfunction in patients with mild 
septal thickening HCM is thought to be caused by 
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Figure 1. A 58- year- old man with hypertrophic cardiomyopathy, mild resting gradients, and 
provocable severe gradients, who subsequently developed severe persistent resting gradients, 
left ventricular (LV) ballooning, and shock.
A, Before the ballooning event, an m- mode echocardiogram is shown at rest through the mitral valve tips, 
showing systolic anterior motion (SAM) with transient mitral- septal contact (red arrows). B, Performed 
after Valsalva shows prolonged mitral- septal contact. Resting LV outflow gradient was 40  mm  Hg, 
increasing to 84 mm Hg after Valsalva. C, Systolic parasternal long- axis view after Valsalva with SAM and 
mitral- septal contact (red arrow). D, Cardiovascular magnetic resonance imaging diastolic 4- chamber 
view with 17- mm anterior septal bulge (yellow arrow). E, Systolic frame. LV systolic function is normal. He 
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Figure 2. Same patient as Figure 1. Two years later, after 3 hours of physical labor, he developed resting chest discomfort, 
hypotension (blood pressure, 78/50 mm Hg), pulmonary edema, new ST- segment elevation anteriorly, and an elevated 
troponin I of 6 ng/mL.
His echocardiogram then showed the following: A, Diastolic apical 4- chamber view showing the ballooned apical and mid left 
ventricular (LV) segments (arrowheads). There is mild asymmetric hypertrophy. Anterior mitral valve leaflet was elongated at 29 mm. 
B, Systolic apical 4- chamber view showing mitral- septal contact and the ballooned dyskinetic and akinetic mid and apical segments 
(arrowheads) with systolic anterior motion (SAM) of the mitral valve and mitral- septal contact (red arrow). The resting Doppler LV 
outflow tract gradient was 135 mm Hg. C, Diastolic parasternal long- axis view showing apical mid ballooning. D, Systolic parasternal 
long- axis view showing apical- mid ballooning and mitral- septal contact (red arrow). E, Severe, laterally directed mitral regurgitation 
(yellow arrow). He was treated with intravenous (IV) metoprolol and IV phenylephrine. After 2 days of shock and persistent hypotension, 
he could be weaned from parenteral therapy and was discharged on oral β- blocker. Echocardiogram performed 6 weeks later showed 
hypertrophic cardiomyopathy (HCM), mild septal hypertrophy (13– 14  mm), normal thickness of remaining segments, normal LV 
systolic function, resting SAM, and gradient of 40 mm Hg. Over the ensuing months, he had limiting symptoms and higher resting 
gradients with mitral regurgitation despite pharmacologic treatment, and thus was referred for extended surgical septal myectomy, 
with improvement of symptoms. He is now New York Heart Association class II 4 months after surgery. Case demonstrates how 
a patient with stable HCM and provocable obstruction with normal LV systolic function can suddenly develop unrelenting severe 
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Four lines of evidence support this pathophysiol-
ogy: (1) Severe LV outflow obstruction can cause 
severe ischemia, documented by coronary vein 
lactate production and nuclear and positron emis-
sion tomography techniques. Supply- demand 
ischemia results from elevated LV systolic pres-
sure and work, lowered diastolic BP with coronary 
underperfusion, narrowed intramural coronaries, 
and microvascular dysfunction. (2) Doppler evi-
dence of inability to overcome afterload. With gra-
dients ≥60 mm Hg, there is a ubiquitous reversible 
midsystolic decrease in LV pulsed Doppler ejec-
tion velocities and flow10 attributable to premature 
termination of segmental contraction.11 This is an 
afterload mismatch phenomena, first observed 
in patients with obstructive HCM 24  years ago,10 
collectively termed “paradoxical reversible systolic 
dysfunction.” Systolic impairment is paradoxical 
because HCM is understood as a hyperdynamic 
condition. This is evidence of instantaneous sys-
tolic heart failure attributable to afterload. We 
believe that ballooning in HCM is a more severe 
manifestation of dynamic systolic dysfunction at-
tributable to sudden outflow obstruction. (3) We 
have not observed LV ballooning in our patients 
with nonobstructive HCM, nor, to our knowledge, 
has it been reported in the literature. This under-
scores the causative importance of high gradients 
in ballooning. (4) The rapid resolution of refractory 
shock and severe LV systolic dysfunction after sep-
tal reduction in 6 of our patients is compelling evi-
dence that obstruction causes the LV dysfunction. 
Two patients had rapid improvement in LV function 
within 2 hours of surgery.3
In apical ballooning, it has been proposed that out-
flow obstruction results from a narrowed hyperkinetic 
outflow tract, with development of Venturi forces there, 
attributable to functional alteration of LV geometry. 
However, the weight of evidence about SAM in HCM 
is that it is caused by flow drag, the pushing force of 
flow, and not by a Venturi effect. Outflow velocities are 
low in obstructive HCM when SAM begins, preclud-
ing Venturi forces as a mechanism.12,13 In patients with 
obstructed HCM with apical ballooning, we propose 
that mitral- septal contact is not a result of wall motion 
abnormalities, but instead may be their cause.1- 3
We previously reported that an episode of acute 
apical ballooning occurred in about 1% of patients in 
our prospectively acquired database of patients with 
HCM.2 Of those with ballooning, cardiogenic shock 
occurred in a third. A common denominator of the pa-
tients with obstructive HCM with ballooning has been 
relatively mild septal thickening, about 15  mm, less 
than in our other patients with HCM, 20  mm,1,2 and 
now, in patients with obstructive HCM with shock, 
where septal thickness was 16 mm. We hypothesize 
that in the typical patient with HCM, severe hypertro-
phy acts as a buttress to prevent the development 
of ballooning. In contrast, in patients with ballooning, 
mildly thickened walls may be unprepared to perform 
in the face of high LV pressures, and extremely high 
wall stress. (Wall thickness is in the denominator of the 
wall stress equation.)
In obstructive HCM, mitral regurgitation is caused 
by SAM and dynamic deformation of the mitral valve. 
Of the 14 patients, 5 had severe mitral regurgitation 
associated with outflow gradients that undoubtedly 
contributed to their low stroke volume and shock.
Therapy
Because LV outflow gradients are the cause of the 
acute deterioration, therapy is targeted to abolish 
SAM and mitral- septal contact. Initial measures de-
signed to reverse provoking causes are administered: 
intravenous fluids for volume depletion, blood trans-
fusion for anemia, and urgent cardioversion for rapid 
atrial fibrillation. The mainstay of therapy of patients 
with HCM with apical ballooning, but without hemo-
dynamic instability, is β- blocker therapy, administered 
intravenously.2 Although it may seem counterintui-
tive to treat with β- blockers when BP is borderline 
or low, nevertheless in our experience, LV outflow 
gradients often decrease, and BP either increases or 
remains unchanged. We typically administer intrave-
nous metoprolol, 15 mg, over 15 minutes with careful 
monitoring of BP and heart rate. We have found such 
therapy to be safe in this scenario. Esmolol infusion is 
an alternative; however, titration may require time. We 
therefore prefer metoprolol. However, when hypoten-
sion and poor tissue perfusion are evident, pharma-
cologic choices become limited. We are reticent to 
administer metoprolol alone to patients with systolic 
BP <80 mm Hg; when this occurs, the combination 
of phenylephrine to support BP along with metopro-
lol is preferred.
Positive inotropic agents, such as dopamine, dobu-
tamine, and milrinone, should be explicitly avoided 
because the drugs worsen dynamic obstruction and 
exacerbate shock. Six of our patients could be suc-
cessfully managed by reversing outflow obstruction 
with pharmacotherapy, whereas the majority required 
advanced invasive therapy.
Mechanical Circulatory Support
The differences between methods of invasive circula-
tory support have previously been described. Although 
intra- aortic balloon counterpulsation improves coro-
nary perfusion during diastole, the presystolic deflation 
decreases afterload and may thus worsen, or produce 
de novo LV outflow obstruction. The Impella cath-
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preload, and offers partial LV support. However, de-
creasing LV cavity size in HCM may promote SAM and 
increase LV outflow obstruction. The same phenom-
enon may occur with the Tandem Heart. In contrast, 
VA- ECMO increases afterload by retrograde flow, while 
augmenting cardiac output and coronary perfusion. 
Obstructive HCM physiology generally responds well 
to mildly increased afterload. VA- ECMO offers full cir-
culatory support for the sickest patients, and can be 
initiated rapidly at the bedside.
Of the 14 patients, intra- aortic balloon counterpul-
sation was used in 4 and may have aided recovery in 
2, but failed to improve shock in the other 2. VA- ECMO 
stabilized BP in 3 patients who were supported for 4 
to 13 days; its use has been successful in 2 other prior 
reports of shock attributable to LV outflow obstruc-
tion. When it is locally available, VA- ECMO may be the 
best choice for temporary circulatory support, to allow 
the LV to recover, or as a bridge to septal reduction 
therapy. Weaning should be tried after stabilization. 
However, when tapering from VA- ECMO cannot be 
achieved, because of recurrent obstruction, septal 
reduction is the next step. Durable LV assist devices 
have been used successfully in patients with HCM as 
a bridge to transplantation, although small chamber 
sizes and LV muscle bundles can impede the inflow 
cannula. We do not advocate for durable LV assist 
device use herein because relatively rapid, complete 
reversal of abnormal systolic function is expected on 
abolition of outflow obstruction.
Septal Myectomy
Surgical relief of LV outflow obstruction is the defini-
tive therapy to immediately and permanently abol-
ish LV outflow gradient, and to reduce afterload and 
supply- demand ischemia. Of the 14 patients, 5 re-
quired urgent surgical myectomy, 2 with concomi-
tant mitral valve replacement in 2007. In the current 
era, these 2 patients, with septal thicknesses of 16 
and 17 mm, respectively, would not have mitral valve 
replacement; rather, with refined surgical techniques 
developed since then, shallow but extended myec-
tomy would be performed with consideration of an-
cillary mitral valve repair (ie, mitral shortening for an 
elongated anterior leaflet or chordal cutting when 
these structures position the mitral valve in the flow 
stream). However, in that era of ≈2007, mitral valve 
replacement was the norm for patients with thin sep-
tum. In that era, at that time, our judgement was to 
definitively abolish LV outflow obstruction without the 
potential need for a second pump run that the patient 
might not survive. In making these judgements in crit-
ically ill patients, the risk of "undertreating" is greater 
than that of "overtreating.” One additional patient re-
quired surgical myectomy for limiting symptoms and 
gradient 4  months after recovery from the LV bal-
looning event.
One patient had “bail- out” alcohol septal ablation 
performed because multisystem failure precluded 
myectomy. Because alcohol ablation causes a septal 
infarct, there is the potential for exacerbating hemo-
dynamic instability. Also, surgery provides immedi-
ate and reliable relief of obstruction, compared with 
ablation, which may require weeks for effect. For 
these reasons, we recommend surgery over alcohol 
ablation. The institution of cardiopulmonary bypass 
itself can reverse the ischemic process. Indeed, in 
2 patients, after the bypass run and abolishing out-
flow obstruction, we observed improvement in LV 
function almost immediately.3 Although there is un-
derstandable reticence to operate on patients with 
acute myocardial ischemia, cardiogenic shock, and 
systemic acidosis, when pharmacotherapy fails to 
reverse shock, surgical intervention is necessary. 
Indeed, this clinical scenario is one of the few in 
HCM requiring emergent surgical intervention. When 
LV outflow gradients cause obstruction and balloon-
ing, the patients with HCM may be confused with the 
larger group of patients with non- HCM Takotsubo 
syndrome. In this clinical scenario, decisions must 
be made in hours, often in the emergency depart-
ment, and misdiagnosis of the true pathophysiology 
can result in fatal missteps, underscoring the need 
for a prepared team. Familiarity with the many ana-
tomic variants found in HCM, particularly of the mitral 
valve, can speed recognition. Figure S1 summarizes 
our recommended approach for these critically ill 
patients.
We acknowledge the possibility of publication bias; 
patients who do not do well may not be the subject of 
case reports, and patients who have succumbed from 
this syndrome may not have come to our attention. We 
also acknowledge that natural history of LV ballooning 
syndrome often results in spontaneous and complete 
resolution. We believe this would not have been the 
case for our patients who required mechanical support 
and septal reduction who were in extremis before their 
interventions.
CONCLUSIONS
When shock occurs in obstructive HCM with LV 
ballooning, therapy targeted to reduce or abolish 
obstruction may lead to survival with complete re-
covery of LV systolic function. Reversing provok-
ing factors, like dehydration, anemia, and atrial 
fibrillation, should be instituted first. Pharmacologic 
therapy with β- blockade and vasoconstrictor medi-
cation may reverse outflow obstruction and shock. 
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or if the patient cannot be weaned from intravenous 
therapy, circulatory support with VA- ECMO or other 
modalities should be promptly instituted. If mechani-
cal support cannot be discontinued, and high gradi-
ents persist, surgical relief of obstruction should be 
undertaken urgently.
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Table S1. Clinical characteristics of 14 Obstructive HCM Patients with Cardiogenic Shock and Acute 
LV Ballooning  
Author Sex Age Precipitant ECG Trop I  
ng/ml    





Sherrid 2011 3 M  70 Gastroenteritis 
with diarrhea        
LVH with more ST 
depressions 
laterally  
Trop I 1.2 77/42 + 




NM 80/50 0 
Sherrid 2019 2 F 63 gastroenteritis ST elevation and 
Q waves 
anteriorly 
Trop I 2.4 80/60 0 
Sherrid 2019 2  F 66 Delivered eulogy ST depression 
and TWI 
Trop I 1.4 82/59 + 
Sherrid 2019 2 F 61 None LVH, ST elev 1, 
AvL 
Trop I 2.72 83/61 0 
Husaini 2020 4 F 68 Husband's  
severe illness 
LBBB Trop T 0.46 83/59 + 












M 58 Exhaustion p 3 
hrs labor  
Anterior ST 
elevations  
Trop 6 78/50 + 
Yasutoni 1989 11 † 
 
F 63 Uterine CA 
chemo, 
dehydration 
ST elevation and 
TWI 2,3,AvF,V2-
V6;  
CPK 257           
MB 9%.  
58/ 0 
Cevik 2018 6 † 
 
F 69 New onset Afib Afib, LBBB with 
LAD 
NM 70/50 + 
Arakawa 2018 7 † 
 
F 62 Severe emotional 
stress 
ST elevation I, 
aVL, V3-V6 




Nalluri 2018 8 † 
 
F 81 GI bleeding, 
anemia, Afib 
Precordial TWI Trop I 1.26 60/40 + 
Sosalla 2019 9 † 
 
F 78 Extreme weather NM Trop 
elevated 
NM - 
Sato 2020 10 † 
 
F  81 Influenza; afib Anterior ST 
elevation with 
loss of R waves  




74/40   
0 
*Patient reported here for the first time. † Six cases reported by other authors. 
Coro Sten=coronary stenosis; hsTnT=high sensitivity troponin T; NM=not mentioned in case report; 
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Sherrid 2011 3 90 25 17 2 Elong leaf 
Sherrid 2011 3 135 25 16 2 Anom PM 
Sherrid 2019 2 60 30 14 4 Elong leaf; 
Anom PM 
Sherrid 2019 2 80 25 13 4 Elong leaf 
Sherrid 2019 2 100 25 12 NM NM 





30 19 1 Elong leaf 
Caniato 2021 5 90 15 18 3-4 Elong leaf
*Wever-
Pinzon, Fig 1,2
135 30 19 3-4 Elong leaf
Yasutoni 1989 11 
† 
120 NM 20 NM -
Cevik 2018 6 †  >50
"severe"
20 NM NM -
Arakawa 2018 7 
† 




Nalluri 2018 8 †  >90 20-25 ASH 4 - 
Sosalla 2019 9 † 120 30 16-17 4 - 




*Patient reported here for the first time. † Six cases reported by other authors.
Anom PM=anomalous papillary muscle; Elong leaf=Elongated mitral leaflet(s);
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